Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales

Objective:┬áTo evaluate the cost-effectiveness of bendamustine-rituximab (B-R) compared with CHOP-R and CVP-R as first-line treatment for patients with advanced indolent non-Hodgkin’s lymphoma (NHL).